Phase 2 Sickle Cell Disease Trial, Recruiting NCT07023666 Sponsor: Inova Health Care Services Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 2 Sickle Cell Disease Trial, Recruiting

NCT07023666
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 18 years old
  • You have been diagnosed with sickle cell disease (any type or form)
  • Your blood test shows a ferritin (iron) level of 400 ng/mL or higher — OR — your ferritin level is below 400 ng/mL but you have heart-related symptoms such as shortness of breath or swelling in your legs (confirm with trial site)
  • You are willing to have regular heart tests, including echocardiograms, ECGs, and cardiac MRI scans
  • You are generally able to carry out daily activities with no more than mild limitations (confirm with trial site)
  • You are able to read, understand, and sign a consent form
  • Your doctor has agreed that it is appropriate for you to take part

Who may not be able to join:

  • You are unable to attend the required follow-up appointments
  • You have been diagnosed with heart failure
  • You have unstable angina (chest pain that is not controlled)
  • You have an irregular heartbeat that is not under control
  • You have recently had a blood clot in your lungs (acute pulmonary embolism)
  • You currently have an active infection or another serious health condition that the trial doctors feel would prevent safe participation
  • You have had a bad reaction to chelation therapy (treatment to remove excess iron) in the past, or have a medical reason not to use it
  • You have severe kidney or liver problems
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sheinei Alan, MD, Inova Fairfax Hospital

Phone: 571-472-3173

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Inova Health Care Services
Registry
ClinicalTrials.gov
Start date
7 October 2025
Est. completion
30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of Hospitalization for Sickle Cell Disease Related Complications; Length of Stay for SCD-Related Complications

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov